Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients

The investigators included 782 HIV-infected patients from January 2016 to October 2020 Zhongnan Hospital of Wuhan University, whose AIDS diagnosis criteria met the "AIDS Diagnosis and Treatment Guide (2018 edition)" of Chinese Medical Association.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Leukemia Neoplasms Neoplasms by Histologic Type RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HIV-infection

Exclusion criteria

Treatment and study plan

Primary outcomes

The proportion of granulocytes and granulocyte/macrophage progenitors in myelogram of HIV/AIDS patients

Time frame: 2020

Flow cytometric immunophenotyping of an EDTA-anticoagulated BM aspirate specimen was performed. A standard BM assay with erythrocyte cell lysis was used for all BM aspirate specimens. Flow cytometric analysis was conducted using a FACS Canto II flow cytometer (Becton Dickinson, Sunnyvale, CA, USA).

Secondary outcomes

Neutrophil counts in peripheral blood of HIV/AIDS patients

Time frame: 2020

Blood samples were drawn from patients undergoing routine diagnostic blood analysis at our institute by sterile venipuncture into tubes containing 5.4 mg of K2EDTA and analyzed by the automated hematology analyzer.

Sponsors and collaborators

Lead sponsor

Zhongnan Hospital

Other

Registry information

Official study title

A Single-center, Retrospective Cohort Study of Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients

Important dates

Study start: 2016
Primary completion: 2020
Study completion: 2022
First posted: Apr 11, 2023
Registry last updated: Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed